Rapid review on the use of oral fatty acid supplements in the prevention or as adjunct treatment of COVID-19
Acta Medica Philippina
;
: 901-945, 2020.
Artículo
en Inglés
| WPRIM
| ID: wpr-979729
ABSTRACT
Key Findings@#There is lack of clinical evidence supporting the role of oral fatty acid supplements as prevention and adjunctive therapy for COVID-19. Long-chain polyunsaturated fatty acids (PUFAs) mediate inflammation and adaptive immune responses. Omega-3 fatty acids promote anti‐inflammatory effects and reduce influenza virus replication. No clinical evidence supporting the use of oral fatty acid supplements as prevention and adjunctive therapy of COVID-19 was found. We found indirect evidence from one systematic review on acute respiratory distress syndrome (ARDS) and two longitudinal cohort studies on community-acquired pneumonia that showed non-significant and inconsistent results. The most common known side effects of omega-3-fatty acids are gastrointestinal in nature. They may also cause allergy and affect blood clotting if taken with other medications that affect clotting. There are 2 ongoing clinical trials on eicosapentaenoic fatty acids as an adjunctive therapy to standard oral nutrition supplements or standard of care in COVID-19 patients. WHO Interim guidelines, CDC interim guidelines, Infectious Diseases Society of America COVID-19 treatment guidelines, and the American Thoracic Society did not give any recommendation on the use of nutritional supplements in patients with COVID-19.
Buscar en Google
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
COVID-19
Tipo de estudio:
Revisiones Sistemáticas Evaluadas
Idioma:
Inglés
Revista:
Acta Medica Philippina
Año:
2020
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS